Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 7686 results

  1. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years TSID 12046

    Awaiting development [GID-TA11632] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Ublituximab for treating relapsing multiple sclerosis [ID6350]

    In development [GID-TA11268] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491

    Awaiting development [GID-TA11075] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

    In development [GID-TA11561] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  5. Direct skeletal fixation of limb prostheses using intraosseous transcutaneous implants

    In development [GID-IPG10351] Expected publication date: 12 December 2024

    Interventional procedures guidance
    In development

  6. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer ID6490

    Awaiting development [GID-TA11624] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Violence and Aggression: short-term management in mental health, health and community settings

    In development [GID-NG10432] Expected publication date: TBC

    NICE guideline
    In development

  8. Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]

    In development [GID-TA11485] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  9. Teprotumumab for treating thyroid eye disease [ID6432]

    In development [GID-TA11531] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  10. Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237]

    Awaiting development [GID-TA10239] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256

    In development [GID-TA11279] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  12. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development [GID-TA11232] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  13. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 20 November 2024.

    Technology appraisal guidance
    In consultation

  14. Vosoritide for treating achondroplasia in people 4 months and over ID6488

    Awaiting development [GID-TA11528] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. One-piece closed bags for adults with a colostomy: Late Stage Assessment

    In development [GID-HTE10045] Expected publication date: TBC

    Health technology evaluations
    In development